Arginine catabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Arginine catabolic process pathway differs between tumor and matched normal tissue in 12 of the 18 cancer types tested.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as BLCA and HNSC, show the opposite pattern, with lower activity in tumor tissue.

BLCA, LUAD, and COAD show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
BLCA	All	All	−0.055	<.001	8	view →
LUAD	All	II,III,IV	+0.076	<.001	7	view →
COAD	All	IV	+0.065	<.001	7	view →
HNSC	Male	All	−0.038	.006	6	view →
CHOL	Male	All	−0.138	<.001	5	view →
LIHC	All	All	−0.041	<.001	5	view →
KIRP	Female	All	+0.071	<.001	4	view →
BRCA	All	IV	−0.079	.036	2	view →
STAD	Male	II,III,IV	+0.044	.036	2	view →
LUSC	All	All	+0.026	.004	2	view →
READ	All	All	+0.052	.022	1	view →
THCA	All	III,IV	+0.029	.022	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 12 lineages.

GO:0006527–BLCA

Open the BLCA breakdown →